Synergistic metabolic benefits of an exenatide analogue and cholecystokinin in diet-induced obese and leptin-deficient rodents

Alternative dosing strategies for liraglutide in patients with type 2 diabetes mellitus

(2014) A. B. Marino et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

The glucagon-like peptide-1-based therapeutics exenatide and saxagliptin did not cause detrimental effects on the pancreas in mice, rats, dogs and monkeys

(2014) D. Roy et al.   DIABETES OBESITY & METABOLISM

Simultaneous quantification of the glucagon-like peptide-1 (GLP-1) and cholecystokinin (CCK) receptor agonists in rodent plasma by on-line solid phase extraction and LC–MS/MS

(2014) Yan Wang et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Occurrence of Spontaneous Pancreatic Lesions in Normal and Diabetic Rats: A Potential Confounding Factor in the Nonclinical Assessment of GLP-1-Based Therapies

(2013) K. D. Chadwick et al.   DIABETES

Synergy: A Concept in Search of a Definition

(2013) Hans-Rudolf Berthoud   ENDOCRINOLOGY

The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis

(2012) Niels Vrang et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Chronic GLP-1 Receptor Activation by Exendin-4 Induces Expansion of Pancreatic Duct Glands in Rats and Accelerates Formation of Dysplastic Lesions and Chronic Pancreatitis in the KrasG12DMouse Model

(2012) Belinda Gier et al.   DIABETES

No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks

(2012) K. Tatarkiewicz et al.   DIABETES OBESITY & METABOLISM

Leptin Resistance in Vagal Afferent Neurons Inhibits Cholecystokinin Signaling and Satiation in Diet Induced Obese Rats

(2012) Guillaume de Lartigue et al.   PLoS One

The common hepatic branch of the vagus is not required to mediate the glycemic and food intake suppressive effects of glucagon-like-peptide-1

(2011) Matthew R. Hayes et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

Intracellular Signals Mediating the Food Intake-Suppressive Effects of Hindbrain Glucagon-like Peptide-1 Receptor Activation

(2011) Matthew R. Hayes et al.   Cell Metabolism

CCK Stimulation of GLP-1 Neurons Involves α 1 -Adrenoceptor–Mediated Increase in Glutamatergic Synaptic Inputs

(2011) Kazunari Hisadome et al.   DIABETES

Potential use of exenatide for the treatment of obesity

(2011) Franco Folli et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial

(2011) Kishore M Gadde et al.   LANCET

Comparative Effects of the Long-Acting GLP-1 Receptor Ligands, Liraglutide and Exendin-4, on Food Intake and Body Weight Suppression in Rats

(2011) Matthew R. Hayes et al.   Obesity

Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents

(2010) Krystyna Tatarkiewicz et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

“Weighing in” on synergy: Preclinical research on neurohormonal anti-obesity combinations

(2010) Jonathan D. Roth et al.   BRAIN RESEARCH

Cholecystokinin Is Up-Regulated in Obese Mouse Islets and Expands β-Cell Mass by Increasing β-Cell Survival

(2010) Jeremy A. Lavine et al.   ENDOCRINOLOGY

Enhanced Weight Loss Following Coadministration of Pramlintide With Sibutramine or Phentermine in a Multicenter Trial

(2010) Louis J. Aronne et al.   Obesity

Multi-hormonal weight loss combinations in diet-induced obese rats: Therapeutic potential of cholecystokinin?

(2010) James L. Trevaskis et al.   PHYSIOLOGY & BEHAVIOR

Role of Fat Hydrolysis in Regulating Glucagon-Like Peptide-1 Secretion

(2009) Svetlana Beglinger et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity

(2008) S. R. Smith et al.   DIABETES CARE

Rational Design of a Combination Medication for the Treatment of Obesity

(2008) Frank L. Greenway et al.   Obesity

Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studies

(2008) J. D. Roth et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA